Rafael Lancelotta

1.4k total citations
20 papers, 912 citations indexed

About

Rafael Lancelotta is a scholar working on Clinical Psychology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Rafael Lancelotta has authored 20 papers receiving a total of 912 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Clinical Psychology, 10 papers in Organic Chemistry and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Rafael Lancelotta's work include Psychedelics and Drug Studies (20 papers), Chemical synthesis and alkaloids (10 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Rafael Lancelotta is often cited by papers focused on Psychedelics and Drug Studies (20 papers), Chemical synthesis and alkaloids (10 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Rafael Lancelotta collaborates with scholars based in United States, Netherlands and United Kingdom. Rafael Lancelotta's co-authors include Alan K. Davis, Malin V. Uthaug, Johannes G. Ramaekers, Joseph P. Barsuglia, Roland R. Griffiths, Geoff J. Bathje, Jason B. Luoma, Christina Chwyl, Robert M. Grant and Jordi Riba and has published in prestigious journals such as PLoS ONE, Journal of Neurochemistry and Journal of Affective Disorders.

In The Last Decade

Rafael Lancelotta

20 papers receiving 886 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rafael Lancelotta United States	14	856	501	370	141	88	20	912
Malin V. Uthaug Netherlands	14	849 1.0×	468 0.9×	370 1.0×	209 1.5×	74 0.8×	21	900
Theresa M. Carbonaro United States	11	864 1.0×	538 1.1×	429 1.2×	168 1.2×	49 0.6×	17	970
Jonny Martell United Kingdom	6	1.0k 1.2×	685 1.4×	522 1.4×	120 0.9×	115 1.3×	7	1.1k
Teri Suzanne Krebs Norway	4	832 1.0×	440 0.9×	396 1.1×	150 1.1×	52 0.6×	4	863
Ashleigh Murphy-Beiner United Kingdom	9	1.2k 1.4×	781 1.6×	558 1.5×	133 0.9×	121 1.4×	14	1.3k
Laura Ley Switzerland	14	844 1.0×	516 1.0×	462 1.2×	149 1.1×	61 0.7×	23	897
Nimmy Varghese Switzerland	15	996 1.2×	622 1.2×	591 1.6×	171 1.2×	120 1.4×	30	1.2k
Alicia Danforth United States	7	1.3k 1.5×	722 1.4×	569 1.5×	123 0.9×	83 0.9×	10	1.3k
Jacob S. Aday United States	15	877 1.0×	541 1.1×	328 0.9×	121 0.9×	41 0.5×	37	988
Eline Haijen United Kingdom	9	1.1k 1.3×	642 1.3×	465 1.3×	189 1.3×	78 0.9×	15	1.2k

Countries citing papers authored by Rafael Lancelotta

Since Specialization

Citations

This map shows the geographic impact of Rafael Lancelotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael Lancelotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael Lancelotta more than expected).

Fields of papers citing papers by Rafael Lancelotta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafael Lancelotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael Lancelotta. The network helps show where Rafael Lancelotta may publish in the future.

Co-authorship network of co-authors of Rafael Lancelotta

This figure shows the co-authorship network connecting the top 25 collaborators of Rafael Lancelotta. A scholar is included among the top collaborators of Rafael Lancelotta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael Lancelotta. Rafael Lancelotta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lancelotta, Rafael, David I. Quinn, Natalie Gukasyan, et al.. (2025). Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study. Journal of Psychoactive Drugs. 1–14. 2 indexed citations

Wootton, Angie R., et al.. (2025). Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people. International Journal of Transgender Health. 1–16. 1 indexed citations

Lancelotta, Rafael, Nathan D. Sepeda, Natalie Gukasyan, et al.. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLoS ONE. 19(3). e0300501–e0300501. 31 indexed citations

Davis, Alan K., Christopher Timmermann, Rafael Lancelotta, et al.. (2023). Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences. Journal of Psychoactive Drugs. 56(4). 456–466. 1 indexed citations

Davis, Alan K., et al.. (2023). Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ Open. 13(5). e068884–e068884. 8 indexed citations

Reckweg, Johannes T., Malin V. Uthaug, Attila Szabó, et al.. (2022). The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT). Journal of Neurochemistry. 162(1). 128–146. 62 indexed citations

Nikolaidis, Aki, Rafael Lancelotta, Natalie Gukasyan, et al.. (2022). Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders. 324. 239–249. 12 indexed citations

Raison, Charles L., et al.. (2022). Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Frontiers in Psychiatry. 13. 1049643–1049643. 11 indexed citations

Uthaug, Malin V., Alan K. Davis, Sean B. Dolan, et al.. (2021). The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology. 36(3). 309–320. 42 indexed citations

10.

Agin-Liebes, Gabrielle, et al.. (2021). Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology & Translational Science. 4(2). 543–552. 68 indexed citations

11.

Sherwood, Alexander M., et al.. (2020). Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use. ACS Omega. 5(49). 32067–32075. 23 indexed citations

12.

Uthaug, Malin V., et al.. (2020). A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. Data Archiving and Networked Services (DANS). 4(2). 104–113. 17 indexed citations

13.

Lancelotta, Rafael & Alan K. Davis. (2020). Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects. Journal of Psychoactive Drugs. 52(3). 273–281. 21 indexed citations

14.

Luoma, Jason B., Christina Chwyl, Geoff J. Bathje, Alan K. Davis, & Rafael Lancelotta. (2020). A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. Journal of Psychoactive Drugs. 52(4). 289–299. 134 indexed citations

15.

Sepeda, Nathan D., et al.. (2019). Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. 4(2). 114–122. 18 indexed citations

16.

Uthaug, Malin V., Rafael Lancelotta, Attila Szabó, et al.. (2019). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology. 237(3). 773–785. 83 indexed citations

17.

Uthaug, Malin V., Rafael Lancelotta, Kim van Oorsouw, et al.. (2019). A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology. 236(9). 2653–2666. 128 indexed citations

18.

Davis, Alan K., et al.. (2019). 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse. 45(2). 161–169. 96 indexed citations

19.

Barsuglia, Joseph P., Alan K. Davis, Robert L. Palmer, et al.. (2018). Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. Frontiers in Psychology. 9. 2459–2459. 55 indexed citations

20.

Davis, Alan K., et al.. (2018). The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology. 32(7). 779–792. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact